In February, EVP of Access & Pricing Tim Wright presented the second of a series of exclusive updates on Most-Favored-Nation pricing, developed in partnership with The Evidence Base. A more current episode of this series will be available soon. To secure exclusive access to the latest video updates as they happen, please register your interest via the button above.
Most-favored-nation (MFN) pricing proposes linking US drug prices to those paid in selected international reference markets, creating significant uncertainty for manufacturers as policymakers consider multiple implementation pathways.
Building on the earlier video in this series, this video focuses on the newly introduced mandatory MFN models GLOBE (Global Benchmark for Efficient Drug Pricing) and GUARD (Guarding US Medicare Against Rising Drug Costs). Wright outlines what these models entail, how they interact with existing pricing initiatives, and what they could mean for global pricing strategies.
As most-favoured-nation pricing policy continues to evolve, we remain committed to informing our connections and clients of every significant development. Throughout 2026 and in collaboration with The Evidence Base, Tim continues to share regular strategic updates and video commentary on MFN pricing.
Please contact us if you have questions or would like a copy of the slides. Register for future MFN updates.
